{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:07:37Z","timestamp":1793837257553,"version":"4.6.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Individuals and\/or caregivers of individuals affected by spinal muscular atrophy (SMA) completed the 2019 Cure SMA Community Update Survey, online, assessing health-related quality of life (HRQoL), loss of work productivity, and fatigue using the Health Utilities Index Questionnaire (HUI), the Work Productivity and Activity Impairment Questionnaire (WPAI), and the Patient Reported Outcomes Measurement Information System Fatigue Short Form (PROMIS Fatigue SF), respectively. The purpose was to collect baseline quality of life results among individuals affected by SMA using the above Patient Reported Outcome Measures (PROMs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 666 surveys completed between March and May 2019, 478 were included in this analysis, accounting for duplicates, missing data, or deaths. The breakdown across SMA type I, II and III was 25, 47 and 28%, respectively. Responses were characterized by current functional status\/milestone, with subsets for \u201cpermanent ventilation,\u201d \u201cnon-sitters,\u201d \u201csitters,\u201d \u201cwalk with support,\u201d and \u201cwalk alone.\u201d WPAI and HUI respondents included affected adults and caregivers. The PROMIS Fatigue SF was completed by the primary caregiver of affected children.<\/jats:p>\n                    <jats:p>Overall, those affected by a less severe form of SMA and with a higher functional status reported higher HRQoL and lower work productivity and activity impairment. All affected individuals reported higher fatigue levels than the general population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study offers useful insights into the burden of SMA among affected individuals and their caregivers. The results provide a baseline picture of the patient and caregiver experience with SMA in a post-treatment era from which to measure year-over-year changes in quality of life scores from new therapies and improved care. The WPAI demonstrates the significant impact of work productivity among SMA populations. Aspects of the HUI seem more appropriate to certain SMA sub-populations than others. Measures from the PROMIS Fatigue SF appear to under-represent the burden of fatigue often reported by SMA individuals and caregivers; this may, perhaps be due to a lack of sensitivity in the questions associated with fatigue in the SMA affected population, when compared with other studies on this topic. Overall, these results suggest the need for SMA-specific quality of life outcome measures to fully capture clinically meaningful change in the SMA population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-020-01498-2","type":"journal-article","created":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T10:03:06Z","timestamp":1598263386000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the Cure SMA Community Update Survey"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8348-1916","authenticated-orcid":false,"given":"Lisa","family":"Belter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ros\u00e1ngel","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Jarecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,24]]},"reference":[{"issue":"2","key":"1498_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.24497","volume":"51","author":"WD Arnold","year":"2015","unstructured":"Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve. 2015;51(2):157\u201367.","journal-title":"Muscle Nerve"},{"issue":"8","key":"1498_CR2","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/archneurol.2011.74","volume":"68","author":"SJ Kolb","year":"2011","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review. Arch Neurol. 2011;68(8):979\u201384.","journal-title":"Arch Neurol"},{"issue":"9","key":"1498_CR3","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810\u20137.","journal-title":"Neurology."},{"issue":"11","key":"1498_CR4","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo DC, Bertini E, Swoboda KJ, Hwu W-L, TO C, Finkel RS, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842\u201356.","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"1498_CR5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625\u201335.","journal-title":"N Engl J Med"},{"issue":"Suppl. 2","key":"1498_CR6","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.nmd.2018.06.122","volume":"28","author":"LJC Belter","year":"2018","unstructured":"Belter LJC, Paradis A, Jhaveri M, Reyna S, Hobby K. Cure SMA membership: findings from the 2018 membership survey [abstract P.94]. Neuromuscular Disord. 2018;28(Suppl. 2):S58.","journal-title":"Neuromuscular Disord"},{"key":"1498_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12883-015-0473-3","volume":"15","author":"Y Qian","year":"2015","unstructured":"Qian Y, McGraw S, Henne J, Jarecki J, Hobby K, Yeh WS. Understanding the experiences and needs of individuals with spinal muscular atrophy and their parents: a qualitative study. BMC Neurol. 2015;15:217.","journal-title":"BMC Neurol"},{"issue":"5","key":"1498_CR8","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","volume":"52","author":"K Zerres","year":"1995","unstructured":"Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52(5):518\u201323.","journal-title":"Arch Neurol"},{"issue":"6","key":"1498_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11940-019-0568-z","volume":"21","author":"MA Waldrop","year":"2019","unstructured":"Waldrop MA, Kolb SJ. Current treatment options in neurology-SMA therapeutics. Curr Treat Options Neurol. 2019;21(6):25.","journal-title":"Curr Treat Options Neurol"},{"issue":"18","key":"1498_CR10","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332.","journal-title":"N Engl J Med"},{"issue":"1","key":"1498_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13023-019-1052-2","volume":"14","author":"HWY Wan","year":"2019","unstructured":"Wan HWY, Carey KA, D\u2019Silva A, Kasparian NA, Farrar MA. \u201cGetting ready for the adult world\u201d: how adults with spinal muscular atrophy perceive and experience healthcare, transition and well-being. Orphanet J Rare Dis. 2019;14(1):74.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1498_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/13696998.2019.1646263","volume":"23","author":"M Droege","year":"2020","unstructured":"Droege M, Sproule D, Arjunji R, Gauthier-Loiselle M, Cloutier M, Dabbous O. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment. J Med Econ. 2020;23(1):70\u20139.","journal-title":"J Med Econ"},{"issue":"13","key":"1498_CR13","doi-asserted-by":"publisher","first-page":"e1206","DOI":"10.1212\/WNL.0000000000006241","volume":"91","author":"P Mongiovi","year":"2018","unstructured":"Mongiovi P, Dilek N, Garland C, Hunter M, Kissel JT, Luebbe E, et al. Patient reported impact of symptoms in spinal muscular atrophy (PRISM-SMA). Neurology. 2018;91(13):e1206\u2013e14.","journal-title":"Neurology."},{"key":"1498_CR14","volume-title":"The voice of the patient report for spinal muscular atrophy","author":"R Cruz","year":"2018","unstructured":"Cruz R, Lenz M, Belter L, Hobby K, Jarecki J. The voice of the patient report for spinal muscular atrophy; 2018."},{"issue":"5","key":"1498_CR15","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.clinthera.2019.03.012","volume":"41","author":"R Cruz","year":"2019","unstructured":"Cruz R, Belter L, Wasnock M, Nazarelli A, Jarecki J. Evaluating Benefit-risk Decision-making in Spinal Muscular Atrophy: A First-ever Study to Assess Risk Tolerance in the SMA Patient Community. Clin Ther. 2019;41(5):943\u201360.e4.","journal-title":"Clin Ther"},{"key":"1498_CR16","unstructured":"\u00a0Institute for Clinical and Economic Review. Spinraza and Zolgensma for spinal muscular atrophy: effectiveness and value. Final evidence report. 2019. Available at: https:\/\/icer-review.org\/wp-content\/uploads\/2018\/07\/ICER_SMA_Final_Evidence_Report_052419.pdf.\u00a0(updated May 24, 2019)."},{"key":"1498_CR17","unstructured":"Public Comments on ICER report 2019. Available from: https:\/\/icer-review.org\/wp-content\/uploads\/2018\/07\/ICER_SMA_Public_Comments_022219.pdf.\u00a0Accessed 2 Feb 2020."},{"key":"1498_CR18","volume-title":"Should ICER Look at transformative therapies? Journal of clinical pathways","author":"W Wong","year":"2019","unstructured":"Wong W. Should ICER Look at transformative therapies? Journal of clinical pathways; 2019."},{"issue":"5","key":"1498_CR19","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/dmcn.12938","volume":"58","author":"E Landfeldt","year":"2016","unstructured":"Landfeldt E, Lindgren P, Bell CF, Guglieri M, Straub V, Lochmuller H, et al. Health-related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross-sectional study. Dev Med Child Neurol. 2016;58(5):508\u201315.","journal-title":"Dev Med Child Neurol"},{"key":"1498_CR20","volume-title":"Launches Third Annual Community Survey to Address Important Issues in SMA Treatment: Cure SMA","author":"SMA Cure","year":"2019","unstructured":"Cure SMA Launches Third Annual Community Survey to Address Important Issues in SMA Treatment: Cure SMA; 2019. Available from: https:\/\/www.curesma.org\/cure-sma-launches-third-annual-community-survey-to-address-important-issues-in-sma-treatment\/."},{"issue":"2","key":"1498_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3233\/JND-170292","volume":"5","author":"L Belter","year":"2018","unstructured":"Belter L, Cook SF, Crawford TO, Jarecki J, Jones CC, Kissel JT, et al. An overview of the Cure SMA membership database: highlights of key demographic and clinical characteristics of SMA members. J Neuromuscul Dis. 2018;5(2):167\u201376.","journal-title":"J Neuromuscul Dis."},{"issue":"12","key":"1498_CR22","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.nmd.2009.09.009","volume":"19","author":"ST Iannaccone","year":"2009","unstructured":"Iannaccone ST, Hynan LS, Morton A, Buchanan R, Limbers CA, Varni JW, et al. The PedsQL in pediatric patients with spinal muscular atrophy: feasibility, reliability, and validity of the pediatric quality of life inventory generic Core scales and neuromuscular module. Neuromuscul Disord. 2009;19(12):805\u201312.","journal-title":"Neuromuscul Disord"},{"key":"1498_CR23","doi-asserted-by":"publisher","first-page":"S224","DOI":"10.1016\/j.nmd.2017.06.467","volume":"27","author":"L Belter","year":"2017","unstructured":"Belter L, Jarecki J, Hobby K, Teynor M. Family impact and health-related quality of life (HRQoL) of parents and individuals with SMA. Neuromuscul Disord. 2017;27:S224.","journal-title":"Neuromuscul Disord"},{"key":"1498_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1477-7525-1-54","volume":"1","author":"J Horsman","year":"2003","unstructured":"Horsman J, Furlong W, Feeny D, Torrance G. The health utilities index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54.","journal-title":"Health Qual Life Outcomes"},{"key":"1498_CR25","first-page":"478","volume-title":"Health status and health policy: quality of life in health care evaluation and resource allocation","author":"D Patrick","year":"1993","unstructured":"Patrick D, Erickson P. Health status and health policy: quality of life in health care evaluation and resource allocation. New York: Oxford University Press; 1993. p. 478."},{"issue":"2","key":"1498_CR26","first-page":"43","volume":"20","author":"Y Feng","year":"2009","unstructured":"Feng Y, Bernier J, McIntosh C, Orpana H. Validation of disability categories derived from health utilities index mark 3 scores. Health Rep. 2009;20(2):43\u201350.","journal-title":"Health Rep"},{"issue":"5","key":"1498_CR27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"M Reilly","year":"1993","unstructured":"Reilly M, Zbrozek A, Dukes E. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics."},{"issue":"12","key":"1498_CR28","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.nmd.2019.10.001","volume":"29","author":"S Messina","year":"2019","unstructured":"Messina S, Frongia AL, Antonaci L, Pera MC, Coratti G, Pane M, et al. A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy. Neuromuscul Disord. 2019;29(12):940\u201350.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"1498_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12883-017-0853-y","volume":"17","author":"S McGraw","year":"2017","unstructured":"McGraw S, Qian Y, Henne J, Jarecki J, Hobby K, Yeh WS. A qualitative study of perceptions of meaningful change in spinal muscular atrophy. BMC Neurol. 2017;17(1):68.","journal-title":"BMC Neurol"},{"issue":"1","key":"1498_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3233\/JND-180342","volume":"6","author":"S Dunaway Young","year":"2019","unstructured":"Dunaway Young S, Montes J, Kramer SS, Podwika B, Rao AK, De Vivo DC. Perceived fatigue in spinal muscular atrophy: a pilot study. J Neuromuscul Dis. 2019;6(1):109\u201317.","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"1498_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12883-019-1244-3","volume":"19","author":"B Bartels","year":"2019","unstructured":"Bartels B, Habets LE, Stam M, Wadman RI, Wijngaarde CA, Schoenmakers MAGC, et al. Assessment of fatigability in patients with spinal muscular atrophy: development and content validity of a set of endurance tests. BMC Neurol. 2019;19(1):21.","journal-title":"BMC Neurol"},{"key":"1498_CR32","unstructured":"Fatigue. A brief guide to the PROMIS Fatigue instruments. Patient-Reported Outcomes Measurement Information System 2019."},{"key":"1498_CR33","doi-asserted-by":"crossref","unstructured":"Rouault F, Christie-Brown V, Broekgaarden R, Gusset N, Henderson D, Marczuk P, et al. Disease impact on general well-being and therapeutic expectations of European type II and type III spinal muscular atrophy patients. Neuromuscul Disord. 2017;27(5):428\u2013438.","DOI":"10.1016\/j.nmd.2017.01.018"},{"key":"1498_CR34","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2147\/CEOR.S214084","volume":"11","author":"AJ Lloyd","year":"2019","unstructured":"Lloyd AJ, Thompson R, Gallop K, Teynor M. Estimation of the quality of life benefits associated with treatment for spinal muscular atrophy. Clinicoecon Outcomes Res. 2019;11:615\u201322.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"Suppl 1","key":"1498_CR35","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1093\/clinids\/18.Supplement_1.S79","volume":"18","author":"JD Fisk","year":"1994","unstructured":"Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis. 1994;18(Suppl 1):S79\u201383.","journal-title":"Clin Infect Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01498-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01498-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01498-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T20:30:12Z","timestamp":1629750612000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01498-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,24]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1498"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01498-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-26971\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-26971\/v2","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,24]]},"assertion":[{"value":"5 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethics approval for this study was granted by Western IRB (IRB Report ID: 1182230). Informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"217"}}